If minor drug drug interactions may have a clinically significant impact is discussed controversely in the literature. However, there is clear evidence, that multiple impacts due to drug drug interactions where several enzymes or transporters are involved may cause huge increases in drug exposures. And there is also evidence for scenarios where multiple minor effects lead to significant changes of the safety profile of a substrate. Often such outcomes are additionally favored by patient individual risk factors such as moderate or severe renal failure or pharmacogenomics causing Poor-Metabolizer-Status at some decisive enzyme,  and their underlying drug drug interaction mechanisms are frequently overlooked, underestimated or due to their complexity not easily detectable. These drug risk are so to say hidden and it takes sophisticated software to find them. SCHOLZ DataBank provides with its AI powered MDDI technology and its Adverse Drug Risk Control Panel (ADR CP) the tools to find systematically the hidden drugs risks in a medication as demonstrated in the "Apixaban Case".

For more details read the article published in the Mega Journal of Case Reports.

The MDDI analysis of SCHOLZ DataBank is especially helpful to ensure drug safety in polypharmacy where billions of diverse medications with 5 and more drugs may contain hidden drug risks.